Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease

NCT07694674 · clinicaltrials.gov ↗

RECRUITING

Status

198

Enrollment

OTHER

Sponsor class

Conditions

Inflamatory Bowel Disease
Crohn Disease (CD)

Interventions

BIOLOGICAL: Infliximab
BIOLOGICAL: Adalimumab
BIOLOGICAL: Vedolizumab
BIOLOGICAL: Ustekinumab (UST)

Sponsor

Shanghai 10th People's Hospital